Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The interleukin-3 receptor beta subunit (βc/CD131) is a critical component of the high-affinity receptor complex for interleukin-3 (IL-3), GM-CSF, and IL-5. It functions as a signal transduction subunit, activating intracellular kinases like JAK2 upon ligand engagement. Aberrant activation contributes to malignancies, making it a therapeutic target.
Tagraxofusp: CD123 (IL3RA) targeting fusion protein; Antibody-drug conjugates (experimental): Targeting components of IL-3R pathway
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Interleukin 3 Receptor Beta Subunit (βc).